Please assess the completion status of the following clinical trial:

Trial Title: PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 80 years of age;~* Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification; of the acute arthritis of primary gout;~* At least 2 gout flares in the year prior to the screening visit;~* Serum uric acid greater than or equal to 7.5 mg/dL at the screening visit;~Exclusion Criteria:~* Acute gout flare within 2 weeks of the screening visit or during screening;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the screening visit;~* Previous exposure to Rilonacept;~* Use of allopurinol, benzbromarone, febuxostat, probenecid or sulfinpyrazone within 3 months prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
- Rilonacept 80 mg (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
- Rilonacept 160 mg (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).